MDXXF Stock PharmAla Biotech Holdings (MDXXF, $0.07) entered Downtrend as Momentum indicator drops below 0 level on Nov 28, 2025
at Tickeron.com
This indicator may be signaling that MDXXF's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 55 similar cases where MDXXF's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:
MDXXF in upward trend: price may jump up because it broke its lower Bollinger Band on November 24, 2025
MDXXF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 14 cases where MDXXF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 39 cases where MDXXF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MDXXF moved out of overbought territory on October 30, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 10 similar instances where the indicator moved out of overbought territory. In of the 10 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on November 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXXF as a result. In of 55 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MDXXF turned negative on November 19, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at .
MDXXF moved below its 50-day moving average on November 28, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDXXF crossed bearishly below the 50-day moving average on November 28, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for MDXXF entered a downward trend on November 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.928) is normal, around the industry mean (27.312). P/E Ratio (0.000) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (321.020).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MDXXF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXXF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology